1259519-18-0

Basic information

• Product Name: (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethyl-d6-amino)-2-butenamide
• Synonyms: (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethyl-d6-amino)-2-butenamide
• CAS NO: 1259519-18-0
• Molecular Weight: 563.004
• Mol File: 1259519-18-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethyl-d6-amino)-2-butenamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethyl-d6-amino)-2-butenamide(1259519-18-0)
• EPA Substance Registry System: (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethyl-d6-amino)-2-butenamide(1259519-18-0)

Safety Data

• Hazardous Substances Data: 1259519-18-0(Hazardous Substances Data)

Usage

Uses

Labelled Neratinib (N390090). An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent.

Upstream product

• 848139-78-6 6-amino-4-[[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-7-ethoxyquinoline-3-carbonitrile 
• 1259519-59-9 (E)-4-(dimethyl-d6-amino)but-2-enoic acid hydrochloride 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF

The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R1 to R11 and X are defined herein.